-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.USD↓
Mitarbeiter
4
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von
Dir gefallen die Informationen zu PharmaCyte Biotech, Inc.?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu PharmaCyte Biotech, Inc.?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu PharmaCyte Biotech, Inc.?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu PharmaCyte Biotech, Inc.?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
26 News & Informationen zur PharmaCyte Biotech, Inc. Aktie
PharmaCyte Biotech Establishes 18-Month Shelf Life For Clinical Trial Product In Ongoing Stability Study
PharmaCyte Biotech, Inc. PMCB, a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell
PharmaCyte Biotech : Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
PharmaCyte Biotech, Inc. , a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today… | August 25, 2021
60 Biggest Movers From Yesterday
Gainers Trillium Therapeutics Inc. (NASDAQ:TRIL) shares jumped 188.8% to close at $17.59 on Monday after the company agreed to be acquired by Pf…
25 Stocks Moving in Monday's Pre-Market Session
Gainers Greenpro Capital Corp. (NASDAQ:GRNQ) rose 48.7% to $1.13 in pre-market trading. Greenpro Capital shares gained 16% on Friday after the c…
PharmaCyte Biotech : Announces $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules (Form 8-K)
PharmaCyte Biotech Announces $70 Million Registered Direct Offering
Priced At-the-Market under Nasdaq Rules
LAGUNA HILLS, CA, August 19, 2021 -PharmaCyte… | August 23, 2021
Pre-market Movers: GOVX, PROG, SONN, MRIN, NVIV…
The following are some of the stocks making big moves in Friday's pre-market trading (as of 5.40 A.M. EDT)..
Mid-Afternoon Market Update: Dow Falls 170 Points; DLocal Shares Spike Higher
Toward the end of trading Thursday, the Dow traded down 0.49% to 34,790.15 while the NASDAQ fell 0.07% to 14,515.39. The S&P also fell, d…
Mid-Afternoon Market Update: Dow Falls 170 Points; DLocal Shares Spike Higher
Toward the end of trading Thursday, the Dow traded down 0.49% to 34,790.15 while the NASDAQ fell 0.07% to 14,515.39. The S&P also fell, dropping …
PharmaCyte stock loses half its value, after tripling in two days led to relatively large stock offering
Shares of PharmaCyte Biotech Inc. undefined lost more than half their value in premarket trading Thursday, after the biotechnology company took advantage of…
PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PharmaCyte Biotech, Inc. PMCB (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its
Pre-market Movers: SONN, ESGC, RSLS, DLO, CHRS, VRPX…
The following are some of the stocks making big moves in Thursday's pre-market trading (as of 5.30 A.M. EDT)..
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.08% By Investing.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.08%
A small biopharma stock has spiked 187% as retail traders cheer CEO's roadmap for drug development following Nasdaq listing
Nastasic/Getty Images Pharmacyte Biotech Inc. spiked 187% Wednesday as investors cheered on the CEO's vision for the company following it…
Mid-Morning Market Update: Markets Mixed; Target Reports Upbeat Profit
Following the market opening Wednesday, the Dow traded down 0.12% to 35,300.85 while the NASDAQ rose 0.03% to 14,660.26. The S&P also fell, dropping …
66 Biggest Movers From Yesterday
Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-i…
PharmaCyte Biotech : Releases Statement on Nasdaq Uplisting and Current Business Focus
PharmaCyte Biotech, Inc. , a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today… | August 16, 2021
PharmaCyte Biotech Releases Statement On Nasdaq Uplisting And Current Business Focus
PharmaCyte Biotech, Inc. PMCB (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.04% By Investing.com
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.04%
Mid-Morning Market Update: Markets Edge Higher; Disney Reports Upbeat Q3 Earnings
Following the market opening Friday, the Dow traded up 0.04% to 35,512.89 while the NASDAQ rose 0.20% to 14,845.17. The S&P also rose, gaining…
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Au…
PharmaCyte Biotech Announces Closing Of $15-Million Public Offering
PharmaCyte Biotech, Inc. PMCB (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its
PharmaCyte Biotech Announces Uplist Date To NASDAQ And Pricing Of $15 Million Public Offering
PharmaCyte Biotech, Inc. PMCB (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its
PharmaCyte Biotech Announces Update On Study Progress And Uplist To Nasdaq
PharmaCyte Biotech, Inc. (OTCQB: PMCBD), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell
PharmaCyte Biotech Announces Reverse Stock Split
PharmaCyte Biotech, Inc. (OTCQB: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using
PharmaCyte Biotech Announces Results Of Vote At Annual Meeting Of Stockholders
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell
PharmaCyte Biotech Provides Update On Status Of Activities To Lift Clinical Hold
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell